Group 1 - The core viewpoint of the news highlights the strong performance of the pharmaceutical and medical services sectors, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index rising by 1.52% as of 11:05 AM on January 23, 2026, driven by significant gains in stocks such as Chengdu Xian Dao (+5.48%) and BGI Genomics (+4.25%) [1] - The Ministry of Commerce and eight other departments have issued opinions to promote high-quality development in the drug retail industry, encouraging retail enterprises to participate in centralized drug procurement and to enhance their bargaining power through joint purchasing [1] - The Chinese pharmaceutical industry is at a pivotal point for global value reassessment, with 2026 being a critical year to validate transformation outcomes, as highlighted by CITIC Securities [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [2] - The CSI Innovation Medicine ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index, providing an easy investment option for those without stock accounts through the linked fund [3]

Group 1 - The core viewpoint of the news highlights the growth of the biomedical sector in China's STAR Market, with the STAR Market Biomedical Index rising by 0.29% and specific stocks like Tianzhihang increasing by 14.64% [1] - The National Healthcare Security Administration has released a guideline for pricing surgical and treatment auxiliary medical services, establishing a fee framework for innovative technologies such as surgical robots and remote surgeries, promoting a coefficient-based charging model linked to robotic assistance [1] - Guohai Securities points out that artificial intelligence is accelerating the empowerment of the entire pharmaceutical industry chain, with NVIDIA and Eli Lilly announcing a joint AI innovation lab, investing up to $1 billion over five years to explore AI applications in drug discovery, development, and manufacturing [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the STAR Market Biomedical Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [1] - The STAR Market Medical ETF by Harvest (588700) closely tracks the STAR Market Biomedical Index, providing an easy investment opportunity in the biomedical sector for investors without stock accounts through the Harvest Medical ETF linked fund (021061) [2]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.00% as of January 14, 2026, with Tianzhihang leading the gain at 18.97% and Rongchang Biopharmaceuticals experiencing the largest drop at 9.83% [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing the promotion of intelligent equipment iteration and supporting AI applications in high-end medical equipment and telemedicine [1] - Nvidia and Eli Lilly announced the establishment of an AI joint laboratory, planning to invest up to $1 billion over the next five years to accelerate drug development, indicating increased investment from leading overseas companies in domestic related fields [1] Group 2 - CITIC Securities reported that the medical AI sector is expected to accelerate the restructuring of the trillion-yuan pharmaceutical market, with a fundamental change in the payment logic for AI medical services anticipated in 2026 [2] - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 48.85% as of December 31, 2025, including companies like United Imaging Healthcare and BeiGene [2] Group 3 - The Jiashi Sci-Tech Medical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, providing an opportunity for investors to easily access the biopharmaceutical sector [3]

Core Insights - The pharmaceutical sector is experiencing a rise, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index increasing by 1.03% as of December 4, 2025, with notable gains from companies like Zai Lab (up 4.47%) and Rongchang Bio (up 4.14%) [1] Industry Overview - The pharmaceutical industry has undergone eleven rounds of national drug centralized procurement and multiple rounds of medical insurance negotiations, leading to an inevitable decline in the generic drug sector, which impacts the overall pharmaceutical industry [1] - From January to September 2025, the pharmaceutical manufacturing industry's revenue remained relatively stable, but the outlook for generic drugs is bleak, indicating a need for innovative drugs to drive future growth [1] Investment Perspective - According to Everbright Securities, future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing clinical needs of patients, as both domestic medical insurance policies and global expansion strategies increasingly emphasize clinical value [1] - The innovative drug industry chain and innovative medical devices are viewed positively based on the clinical value framework [1] Market Data - As of November 28, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 49.75% of the index [1]

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi has a turnover rate of 24.54%, with a trading volume of 59.44 million yuan, indicating active market trading [2] - As of August 11, the Kexin Pharmaceutical ETF managed by Jiashi has reached a recent high in scale of 243 million yuan, ranking first among comparable funds [2] - The latest share count for the Kexin Pharmaceutical ETF managed by Jiashi is 205 million shares, also a recent high, and ranks first among comparable funds [2] Group 2: Fund Inflows and Returns - The Kexin Pharmaceutical ETF managed by Jiashi has seen a net inflow of 2.94 million yuan recently, with 4 out of the last 5 trading days showing net inflows totaling 20.52 million yuan [2] - As of August 11, the Kexin Pharmaceutical ETF managed by Jiashi has achieved a net value increase of 52.43% over the past year, ranking 584 out of 2954 in the index stock fund category, placing it in the top 19.77% [2] - Since its inception, the Kexin Pharmaceutical ETF managed by Jiashi has recorded a highest monthly return of 23.29%, with the longest consecutive monthly gains being 6 months and a maximum cumulative increase of 41.76% [2] Group 3: Top Holdings and Market Trends - As of July 31, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for a total of 49.14%, with leading companies including United Imaging Healthcare and BeiGene [2] - The innovative drug sector has maintained rapid growth in product revenue and external licensing over the past three years, with significant BD transactions this year driving the overall market trend [4] - The innovative drug sector is expected to sustain its growth due to ongoing policy support and increasing global competitiveness, while the medical device industry is anticipated to improve by 2025 [5]

Group 1 - The market experienced a slight decline on the first trading day of August, with the Shanghai Composite Index down by 0.19% at midday [1] - The introduction of the "newly listed drug initial pricing mechanism" by the National Healthcare Security Administration (NHSA) has positively impacted the innovative drug sector, leading to several stocks reaching historical highs [1] - The "biological vaccine ETF" (562860), "Kechuang pharmaceutical ETF" (588700), and "Hang Seng medical ETF" (159557) all saw gains exceeding 0.5%, with the biological vaccine ETF leading the pack at 0.80% [1] Group 2 - As of July 31, the biological vaccine ETF (562860) and Kechuang pharmaceutical ETF (588700) had assets under management of 272 million and 217 million respectively, making them the largest in their respective categories [1] - Multiple institutions maintain a relatively optimistic outlook on the innovative drug market, with CITIC Securities noting that the development of innovative drugs in China has achieved significant progress [2] - Industrial trends such as "innovation + internationalization" are expected to remain core directions for the pharmaceutical sector, supported by policy initiatives and enhanced global competitiveness [2]

Group 1 - The core viewpoint highlights the strong performance and liquidity of the Science and Technology Innovation Pharmaceutical ETF managed by Harvest, which has seen significant trading activity and growth in both scale and shares [2] - As of July 28, the ETF recorded a turnover rate of 22.91% and a transaction volume of 48.1073 million yuan, indicating active market participation [2] - The ETF's net asset value increased by 54.52% over the past year, ranking it in the top 12.25% among comparable index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - Recent collaboration between Hengrui Medicine and GlaxoSmithKline (GSK) involves the joint development of up to 12 innovative drugs, with GSK making an initial payment of 500 million USD and potential milestone payments totaling around 12 billion USD [4] - The pharmaceutical industry is experiencing high growth, with recommendations for companies in Pharma and Biopharma/Biotech sectors as they enter a phase of performance expansion [5]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 0.89% as of July 2, 2025, with mixed performance among constituent stocks [1] - Microchip Biotech led the gains with an increase of 9.47%, followed by Yuyuan Pharmaceutical at 3.45% and Junshi Biosciences at 2.05%, while Rongchang Biotech, Weigao Orthopedics, and BeiGene experienced declines [1] - The CSI Sci-Tech Medicine ETF (Jia Shi) adjusted its holdings [1] Group 2 - The CSI Sci-Tech Medicine ETF (Jia Shi) had a turnover rate of 2.46% and a trading volume of 5.4294 million yuan, with an average daily trading volume of 39.1454 million yuan over the past month, ranking first among comparable funds [3] - The ETF's scale increased by 15.801 million yuan over the past week, also ranking first among comparable funds, with a growth of 12.5 million shares [3] - The latest net inflow of funds into the ETF was 10.4149 million yuan, with a total net inflow of 15.5373 million yuan over the last five trading days [3] - The net value of the ETF increased by 32.18% over the past year, with the highest single-month return since inception being 23.29% and the longest consecutive monthly gain being five months [3] Group 3 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 50.3%, including United Imaging Healthcare, BeiGene, and Huatai Medical [3][5] - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, including increased support for R&D and inclusion in insurance directories [5] Group 4 - Zhongtai Securities believes that innovative drugs will remain the main investment theme in the pharmaceutical sector for the year, with expectations of continued growth amid differentiation [6] - Guolian Minsheng Securities anticipates that 2025 will be a significant year for domestic innovative drugs to enter international markets, following a shift from generic to innovative drugs over the past seven years [6] - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the CSI Sci-Tech Medicine ETF (Jia Shi) linked fund [6]